Paul Tudor Jones Vaxcyte, Inc. Transaction History
Tudor Investment Corp Et Al
- $44 Billion
- Q2 2025
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 53,082 shares of PCVX stock, worth $2.25 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,082Holding current value
$2.25 Million% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding PCVX
# of Institutions
322Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$622 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$508 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$507 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$421 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$254 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.51B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...